Exact Sciences
Market Cap
US$8.6b
Last Updated
2020/03/31 00:28 UTC
Data Sources
Company Financials +
Executive Summary
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally.
Rewards
Risk Analysis
Snowflake Analysis
High growth potential with mediocre balance sheet.
Similar Companies
Share Price & News
How has Exact Sciences's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: EXAS's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
6.6%
EXAS
4.7%
US Biotechs
7.2%
US Market
1 Year Return
-36.4%
EXAS
1.8%
US Biotechs
-10.4%
US Market
Return vs Industry: EXAS underperformed the US Biotechs industry which returned -0.7% over the past year.
Return vs Market: EXAS underperformed the US Market which returned -12.7% over the past year.
Shareholder returns
| EXAS | Industry | Market | |
|---|---|---|---|
| 7 Day | 6.6% | 4.7% | 7.2% |
| 30 Day | -27.8% | -3.5% | -12.6% |
| 90 Day | -36.8% | -5.4% | -19.4% |
| 1 Year | -36.4%-36.4% | 2.6%1.8% | -8.5%-10.4% |
| 3 Year | 157.5%157.5% | 14.0%11.1% | 15.8%8.3% |
| 5 Year | 166.8%166.8% | -3.6%-7.9% | 35.8%21.0% |
Price Volatility Vs. Market
How volatile is Exact Sciences's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall St
Exact Sciences Corporation (NASDAQ:EXAS): Is Breakeven Near?2 months ago | Simply Wall St
How Much is Exact Sciences Corporation's (NASDAQ:EXAS) CEO Getting Paid?2 months ago | Simply Wall St
Investors Who Bought Exact Sciences (NASDAQ:EXAS) Shares Three Years Ago Are Now Up 443%Valuation
Is Exact Sciences undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: EXAS ($57.77) is trading below our estimate of fair value ($177.4)
Significantly Below Fair Value: EXAS is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: EXAS is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: EXAS is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate EXAS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: EXAS is overvalued based on its PB Ratio (3.7x) compared to the US Biotechs industry average (2.5x).
Next Steps
Future Growth
How is Exact Sciences forecast to perform in the next 1 to 3 years based on estimates from 14 analysts?
50.0%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EXAS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).
Earnings vs Market: EXAS is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: EXAS's is expected to become profitable in the next 3 years.
Revenue vs Market: EXAS's revenue (23.4% per year) is forecast to grow faster than the US market (7.3% per year).
High Growth Revenue: EXAS's revenue (23.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: EXAS's Return on Equity is forecast to be low in 3 years time (6.9%).
Next Steps
Past Performance
How has Exact Sciences performed over the past 5 years?
-4.5%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: EXAS is currently unprofitable.
Growing Profit Margin: EXAS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: EXAS is unprofitable, and losses have increased over the past 5 years at a rate of -4.5% per year.
Accelerating Growth: Unable to compare EXAS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EXAS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22%).
Return on Equity
High ROE: EXAS has a negative Return on Equity (-3.67%), as it is currently unprofitable.
Next Steps
Financial Health
How is Exact Sciences's financial position?
Financial Position Analysis
Short Term Liabilities: EXAS's short term assets ($557.0M) exceed its short term liabilities ($236.5M).
Long Term Liabilities: EXAS's short term assets ($557.0M) do not cover its long term liabilities ($981.2M).
Debt to Equity History and Analysis
Debt Level: EXAS's debt to equity ratio (36.5%) is considered satisfactory.
Reducing Debt: EXAS's debt to equity ratio has increased from 0.5% to 36.5% over the past 5 years.
Balance Sheet
Inventory Level: EXAS has a low level of unsold assets or inventory.
Debt Coverage by Assets: EXAS's debt is not covered by short term assets (assets are 0.7x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: EXAS has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if EXAS has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is Exact Sciences's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate EXAS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate EXAS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if EXAS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if EXAS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of EXAS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.3yrs
Average management tenure
CEO
Kevin Conroy (53yo)
10.83s
Tenure
US$6,991,997
Compensation
Mr. Kevin T. Conroy serves as Director of Adaptive Biotechnologies Corporation since April 2019. Mr. Conroy serves as Director at ARYA Sciences Acquisition Corp. Mr. Conroy has been the Chief Executive Off ...
CEO Compensation Analysis
Compensation vs Market: Kevin's total compensation ($USD6.99M) is about average for companies of similar size in the US market ($USD7.36M).
Compensation vs Earnings: Kevin's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board | 10.83yrs | US$6.99m | 0.73% $63.4m | |
| Chief Financial Officer | 3.25yrs | US$1.98m | 0.040% $3.5m | |
| Chief Administrative Officer | 1.67yrs | US$2.09m | 0.072% $6.3m | |
| President of Cologuard | 1.83yrs | US$3.86m | 0.011% $985.6k | |
| Senior Vice President of Operations | 5.17yrs | no data | 0.052% $4.5m | |
| Chief Information Officer | 5.17yrs | no data | no data | |
| Chief Science Officer and Senior VP of Research & Development | 1.17yrs | no data | 0.0084% $730.6k | |
| Associate Manager of Investor Relations | no data | no data | no data | |
| Chief Compliance Counsel & VP | 5.17yrs | no data | no data | |
| Head of Sales | 1.25yrs | no data | no data |
3.3yrs
Average Tenure
53yo
Average Age
Experienced Management: EXAS's management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board | 10.83yrs | US$6.99m | 0.73% $63.4m | |
| Director | 0.67yr | no data | 0.0046% $402.0k | |
| Independent Director | 9.67yrs | US$272.47k | 0.0084% $728.0k | |
| Independent Director | 5yrs | US$274.97k | 0.0060% $520.5k | |
| Independent Director | 10.83yrs | US$269.97k | 0.052% $4.5m | |
| Independent Director | 2.25yrs | US$474.41k | 0.0045% $392.5k | |
| Independent Director | 1yr | no data | 0.0055% $479.0k | |
| Independent Director | 6.83yrs | US$256.47k | 0.023% $2.0m | |
| Independent Director | 5.67yrs | US$266.47k | 0.022% $1.9m | |
| Director | 0.67yr | no data | 0.0040% $349.3k |
5.3yrs
Average Tenure
64yo
Average Age
Experienced Board: EXAS's board of directors are considered experienced (5.3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 7.4%.
Top Shareholders
Company Information
Exact Sciences Corporation's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Exact Sciences Corporation
- Ticker: EXAS
- Exchange: NasdaqCM
- Founded: 1995
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$8.646b
- Shares outstanding: 147.97m
- Website: https://www.exactsciences.com
Number of Employees
Location
- Exact Sciences Corporation
- 441 Charmany Drive
- Madison
- Wisconsin
- 53719
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| EXAS | NasdaqCM (Nasdaq Capital Market) | Yes | Common Stock | US | USD | Jan 2001 |
| EXK | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jan 2001 |
| EXK | BRSE (Berne Stock Exchange) | Yes | Common Stock | CH | CHF | Jan 2001 |
Biography
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; and Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer. The company’s pipeline products focuses on the research and development of enhancing Cologuard's performance characteristics, and blood or other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; Biocartis N.V.; and Hologic, Inc. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/03/31 00:28 |
| End of Day Share Price | 2020/03/30 00:00 |
| Earnings | 2019/12/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.